Related Experiment Video
Updated: Jul 23, 2025
Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
Published on: November 8, 2018
Lestaurtinib (CEP-701) reduces the duration of limbic status epilepticus in periadolescent rats
Yara Mrad1, Reem El Jammal2, Helene Hajjar1
1Department of Anatomy, Cell Biology and Physiological Sciences, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
Insights
Lestaurtinib (CEP-701) significantly shortened status epilepticus (SE) duration and reduced brain injury in rats. This TrkB receptor antagonist shows promise as an adjuvant therapy for SE when standard treatments fail.
Area of Science:
- Neuroscience
- Pharmacology
- Epilepsy Research
Background:
- Status epilepticus (SE) is a medical emergency requiring prompt treatment to prevent brain damage.
- Current anti-seizure medications are ineffective in approximately 30% of pediatric cases.
- The tropomyosin-related kinase B (TrkB) receptor plays a role in neuronal hyperexcitability.
Purpose of the Study:
- To investigate if lestaurtinib (CEP-701), a TrkB receptor antagonist, improves SE treatment response.
- To determine if CEP-701 reduces SE-associated brain injury.
Main Methods:
- Status epilepticus was induced in rats using intra-amygdalar kainic acid.
- Rats received either CEP-701 or vehicle 15 minutes after SE onset.
- Standard anti-seizure drugs (diazepam and levetiracetam) were administered to all groups.
- Brain tissue was analyzed for TrkB dimerization, neuronal density, and GFAP levels.
Main Results:
- CEP-701 treatment reduced SE duration by 50% compared to vehicle.
- SE increased TrkB dimerization, an effect blocked by CEP-701.
- CEP-701 treatment led to lower GFAP levels, indicating reduced neuroinflammation.
- Neuronal density was reduced by SE, with no significant difference between CEP-701 and vehicle groups.
Conclusions:
- Lestaurtinib (CEP-701) effectively shortens SE duration and mitigates associated brain injury.
- CEP-701's ability to block TrkB dimerization is a key mechanism.
- CEP-701 is a potential adjuvant therapy for SE, especially in treatment-resistant cases.
Background:
The timely abortion of status epilepticus (SE) is essential to avoid brain damage and long-term neurodevelopmental sequalae. However, available anti-seizure treatments fail to abort SE in 30% of children. Given the role of the tropomyosin-related kinase B (TrkB) receptor in hyperexcitability, we investigated if TrkB blockade with lestaurtinib (CEP-701) enhances the response of SE to a standard treatment protocol and reduces SE-related brain injury.
Methods:
SE was induced with intra-amygdalar kainic acid in postnatal day 45 rats under continuous electroencephalogram (EEG). Fifteen min post-SE onset, rats received intraperitoneal (i.p.) CEP-701 (KCEP group) or its vehicle (KV group). Controls received CEP-701 or its vehicle following intra-amygdalar saline. All groups received two i.p. doses of diazepam, followed by i.p. levetiracetam at 15 min intervals post-SE onset. Hippocampal TrkB dimer to monomer ratios were assessed by immunoblot 24 hr post-SE, along with neuronal densities and glial fibrillary acid protein (GFAP) levels.
Results:
SE duration was 50% shorter in the KCEP group compared to KV (p < 0.05). Compared to controls, SE induced a 1.5-fold increase in TrkB dimerization in KV rats (p < 0.05), but not in KCEP rats which were comparable to controls (p > 0.05). The KCEP group had lower GFAP levels than KV (p < 0.05), and both were higher than controls (p < 0.05). KCEP and KV rats had comparable hippocampal neuronal densities (p > 0.05), and both were lower than controls (p < 0.05).
Conclusions:
Given its established human safety, CEP-701 is a promising adjuvant drug for the timely abortion of SE and the attenuation of SE-related brain injury.
More Related Videos
Related Concept Videos
01:24Arteries of the Lower Limbs
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...